| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Agilent Technologies, Inc.$139.1
-0.69 (-0.49%)
Market Cap
38.14 B
EPS
5.00
P/E Ratio
27.12 $
Value Trade
401.66 M
SEC Financials
Q2 2026Dilution Risk
Revenue
1.83 B
R&D Expenses
126.00 M
Total Assets
13.06 B
Total Liabilities
5.94 B
Equity
7.12 B
2.37 %
Week
-6.44 %
1 Month
-8.18 %
3 Month
-20.43 %
6 Month
-13.35 %
5 Year
275 %
All Time
Cash Data
Cash Position
1.81 B
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
Jun 1, 2026
Overview
Volume
1.06 M
52 Week Range
108.35 - 160.27
% held by Insiders
0.33 %
% held by Institutions
92.24 %
Enterprise Value
39.69 B
Total Shares
282.49 M
Short %
2.68 %
Float Shares
282.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Agilent Technologies, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in A
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
A Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AAgilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo
Agilent Technologies Inc. has awarded the Agilent Research Catalyst Award to the Eastern Institute of Technology in Ningbo. This award, presented to Professor Zongwei Cai, acknowledges his significant contributions to developing advanced methods for detecting per- and polyfluoroalkyl substances (PFAS) and other emerging contaminants, highlighting their relevance to environmental and public health.
Read more →AAgilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26
Agilent Technologies Inc. will announce its financial results for Q3 FY 2026 on August 26. The announcement will occur after market close, followed by a conference call at 1:30 p.m. PDT to discuss the results. Investors can access the call via a webcast, with a recording available for 90 days.
Read more →AAgilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Agilent Technologies has announced the receipt of EU certification for its PD-L1 IHC 22C3 pharmDx. This companion diagnostic is designed to help identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1. Eligible patients may benefit from treatment with Merck's KEYTRUDA, an anti-PD-1 therapy.
Read more →AAgilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma
Agilent Technologies has received FDA approval for its PD-L1 IHC 28-8 pharmDx assay. This companion diagnostic is designed to identify patients with esophageal squamous cell carcinoma, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma who may benefit from OPDIVO treatment. This approval marks a significant advancement in personalized cancer therapy.
Read more →AAgilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis
Agilent Technologies has expanded its Altura HPLC column portfolio with the introduction of new size exclusion chromatography (SEC) and PLRP-S columns. These columns are designed to enhance critical analytical workflows in biopharmaceutical development and production. They support various biotherapeutic modalities, including peptides, proteins, and oligonucleotides.
Read more →AAgilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight
Agilent has introduced a new AI-driven analysis module for its xCELLigence RTCA eSight platform. This enhancement aims to improve data analysis capabilities, although specific details about its functionalities and benefits are not provided in the article. The launch reflects Agilent's commitment to integrating advanced technologies into their products.
Read more →AAgilent Completes Acquisition of Biocare Medical
Agilent has successfully completed the acquisition of Biocare Medical. This strategic move is expected to enhance Agilent's capabilities in the medical diagnostics field. Further details regarding the implications of this acquisition have not been disclosed.
Read more →AAgilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Agilent has received FDA approval for the expanded use of its PD-L1 IHC 22C3 pharmDx test on the Dako Omnis platform. This approval covers esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma. The expanded use of this diagnostic tool is expected to enhance treatment options for patients with these cancers.
Read more →A▲ +16.9%on this newsshared move
Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
Agilent has launched OpenLab Sync, a new platform designed to enhance digital execution in laboratories. This tool aims to support guided workflows and improve laboratory efficiency. The introduction of OpenLab Sync reflects Agilent's commitment to innovation in laboratory technology.
Read more →AAgilent Reports Second-Quarter Fiscal Year 2026 Financial Results
Agilent has released its financial results for the second quarter of fiscal year 2026. The report includes key metrics and performance indicators relevant to the company's fiscal health. However, specific details regarding revenue, profit margins, or future guidance were not provided in the article.
Read more →AAgilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control
Agilent has introduced a new Multi-Attribute Method (MAM) solution aimed at improving quality control in the biopharmaceutical sector. This innovative approach is designed to enhance the efficiency of biopharma processes, potentially leading to better product quality and compliance. The launch signifies Agilent's commitment to advancing biopharma technologies.
Read more →AAgilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC Speed
Agilent has introduced the 1290 Infinity III Fluorescence Detector designed for ultra-high-performance liquid chromatography (UHPLC). This new product aims to enhance trace analysis capabilities, although specific details about its features and benefits are not provided in the article.
Read more →AAgilent to Participate in Jefferies Global Healthcare Conference 2026
Agilent Technologies Inc. announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026. The event will take place in New York City at 9:20 EDT. A live audio webcast and replay will be available on Agilent's Investor Relations website.
Read more →AAgilent to Participate in Jefferies Global Healthcare Conference
Agilent is set to participate in the upcoming Jefferies Global Healthcare Conference. This event will provide a platform for Agilent to showcase its innovations and engage with investors. Further details about the company's presentations or specific topics of discussion have not been disclosed.
Read more →AAgilent Names Michael Buckner as Chief Legal Officer
Agilent Technologies Inc. has appointed Michael Buckner as its Chief Legal Officer, effective immediately. Buckner brings extensive experience from his prior role at Danaher Corp., where he oversaw legal strategies for significant mergers and acquisitions. He has also held senior legal positions at General Electric and other organizations, further bolstering his qualifications. Padraig McDonnell, Agilent's CEO, expressed optimism about Buckner's potential contributions to the company's growth and strategic goals.
Read more →AAgilent to Announce Second-Quarter Fiscal Year 2026 Financial Results on May 27
Agilent Technologies Inc. will release its second-quarter financial results for fiscal year 2026 on May 27, following the market's close. A conference call will be held at 1:30 p.m. PDT to discuss these results. The company reported a revenue of $6.95 billion in fiscal year 2025, reflecting its strong market position.
Read more →AAgilent Showcases Cancer Research Solutions at AACR 2026
Agilent presented its cancer research solutions at the AACR 2026 conference. The showcase highlighted advancements in cancer research technologies. Details on specific solutions or innovations were not provided in the article.
Read more →AAgilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Technologies has launched the BioTek Cytation 9, a new cell imaging multimode reader. This innovative platform combines advanced imaging capabilities with multimode microplate reading, designed to enhance research workflows. The Cytation 9 aims to support rigorous demands in pharmaceutical and biotechnology labs, offering faster and more adaptable tools for drug discovery and disease research.
Read more →AAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma
Agilent Technologies has received FDA approval for its PD-L1 IHC 22C3 pharmDx as a companion diagnostic for esophageal or gastroesophageal junction carcinoma. This approval allows for the identification of patients whose tumors express PD-L1, making them eligible for treatment with KEYTRUDA. This marks the eighth indication for the diagnostic, further supporting precision medicine in oncology.
Read more →AAgilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
Agilent Technologies has announced its acquisition of Biocare Medical for $950 million, aiming to enhance its pathology portfolio. Biocare, a leader in clinical pathology, has experienced significant growth since 2021. The acquisition is expected to positively impact Agilent's revenue and margin profile in its first year. The deal is subject to regulatory approvals and is anticipated to close by late 2026.
Read more →AAgilent Reports First-Quarter Fiscal Year 2026 Financial Results
Agilent Technologies reported a revenue of $1.80 billion for Q1 FY2026, marking a 7.0% increase year-over-year. The company raised its full-year revenue outlook and adjusted its non-GAAP EPS guidance upward. Despite facing challenges such as a significant snowstorm, Agilent's strong performance in core revenue growth and margin expansion reflects its effective customer-focused strategy. The company remains optimistic about its growth prospects.
Read more →AAgilent to Participate in TD Cowen’s 46th Annual Health Care Conference
Agilent Technologies Inc. will participate in TD Cowen's 46th Annual Health Care Conference. CFO Adam Elinoff and Head of Investor Relations Tejas Savant will engage in a fireside chat on March 3, 2026, in Boston. A live audio webcast will be available for those unable to attend in person.
Read more →AAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
Agilent Technologies has received FDA approval for PD-L1 IHC 22C3 pharmDx, the first companion diagnostic for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. This diagnostic will help identify patients eligible for KEYTRUDA treatment, enhancing precision medicine in oncology. The approval reflects Agilent's commitment to improving cancer treatment options.
Read more →AAgilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award
Agilent Technologies has awarded Boehringer Ingelheim with the inaugural Instrument Trade-In Impact Award for their outstanding sustainability efforts in 2025. The award recognizes the company's leadership in diverting laboratory instruments from landfills, contributing to a circular economy. Boehringer Ingelheim's initiatives resulted in the highest recovery value among Agilent's partners, showcasing their commitment to sustainable practices.
Read more →AAgilent Showcases Next‑Generation Automated Solutions at SLAS2026
Agilent Technologies will present next-generation automated workflow innovations at the SLAS2026 International Conference & Exhibition in Boston. The company will demonstrate its automation ecosystem, featuring advanced imaging and AI-powered optimization tools. Agilent will also debut a compliance-enabling software module and showcase new lab optimization tools. The event highlights Agilent's commitment to advancing laboratory automation.
Read more →AAgilent to Announce First-Quarter Fiscal Year 2026 Financial Results on Feb. 25
Agilent Technologies Inc. will announce its financial results for the first quarter of fiscal year 2026 on February 25, after market close. A conference call will follow at 1:30 p.m. PST to discuss these results. The company reported a revenue of $6.95 billion in fiscal year 2025, showcasing its strong market position.
Read more →AAgilent Accelerates Digital Pathology with the Launch of the Agilent S540MD Slide Scanner System
Agilent Technologies has launched the Agilent S540MD Slide Scanner System, enhancing digital pathology solutions in key European markets. This scanner is designed for high throughput, capable of handling up to 540 slides with automated scanning modes and AI-assisted tissue detection. The introduction aims to improve diagnostic workflows and operational efficiency in pathology laboratories, addressing the growing demand for digital solutions.
Read more →AAgilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight
Agilent Technologies has launched a new 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system. This upgrade allows the system to be utilized in GMP-regulated environments, enhancing data integrity and audit-readiness. The software includes features such as secure user authentication and electronic signatures, supporting users in both drug discovery and manufacturing settings.
Read more →AAgilent Reports Fourth-Quarter Fiscal Year 2025 Financial Results Delivers solid results in Q4, initiates FY26 guidance Fourth-quarter fiscal year 2025 Revenue of $1.86 billion for the fourth quarter ended
Agilent Technologies reported solid financial results for the fourth quarter of fiscal year 2025, with revenues reaching $1.86 billion, exceeding forecasts and reflecting a year-over-year growth of 9.4%. GAAP net income increased to $434 million, or $1.53 per share, a 25% increase compared to the same period last year. The company also provided a positive outlook for fiscal year 2026, expecting revenue between $7.3 billion and $7.4 billion, signaling continued growth. Agilent's management highlighted their confidence in maintaining momentum in life sciences and diagnostics markets.
Read more →AAgilent Names Adam S. Elinoff as Chief Financial Officer
Agilent Technologies Inc. has appointed Adam S. Elinoff as its new Chief Financial Officer, effective November 17. Elinoff, who has two decades of experience in corporate finance and strategy, previously held significant finance roles at Amgen where he successfully managed a $6 billion P&L. His expertise is expected to help Agilent optimize financial operations and drive innovation. Elinoff succeeds interim CFO Rodney Gonsalves, who will remain with the company as corporate controller and principal accounting officer.
Read more →AAgilent Reports Third-Quarter Fiscal Year 2025 Financial Results Agilent delivers strong revenue growth, raises growth outlook Highlights Revenue of $1.74 billion for the third quarter ended
Agilent Technologies announced strong third-quarter fiscal results for 2025, with revenues reaching $1.74 billion, surpassing initial guidance and reflecting a 10.1% growth compared to the same quarter last year. The company reported a net income increase of 22% year-over-year, with all business segments showing progress. Agilent also revised its full-year revenue forecast to between $6.91 billion and $6.93 billion. The company's management credited their operational transformation and focus on profitable growth for these positive results.
Read more →A▼ -5.9%on this news
Agilent Announces CFO Transition
Agilent Technologies Inc. has announced the resignation of its Chief Financial Officer, Bob McMahon, who will step down effective July 31 due to family reasons. Rodney Gonsalves, the current corporate controller, will serve as interim CFO until a successor is appointed. The company expresses gratitude for McMahon's contributions over the past seven years and maintains confidence in Gonsalves' capabilities. Additionally, Agilent's financial results for Q3 FY2025 are expected to align with previously provided guidance.
Read more →AAgilent Reports Second-Quarter Fiscal Year 2025 Financial Results Agilent delivers strong quarter, enabled by Ignite Transformation Highlights Revenue of $1.67 billion for the second quarter ended
Agilent Technologies Inc. reported strong financial results for the second quarter of fiscal year 2025, with revenue of $1.67 billion, an increase of 6.0% year-over-year. Non-GAAP net income rose to $373 million, up 7% from the previous year, although GAAP net income saw a significant decline of 29%. The company projects revenue growth for the full fiscal year between $6.73 billion to $6.81 billion, while also anticipating a positive outlook for Q3. Agilent's Ignite Transformation initiative is credited with driving financial performance amid a dynamic market environment.
Read more →APascal Soriot and Judy Gawlik Brown Named to Agilent Board of Directors Global life-sciences and financial leaders bring decades of health-care, biopharma, and strategic expertise to support Agilent's next phase of growt
Agilent Technologies Inc. announced the appointment of Pascal Soriot and Judy Gawlik Brown to its Board of Directors, effective May 21, 2025. Soriot, CEO of AstraZeneca, and Gawlik Brown, founder of Downtown Advisory, bring years of leadership experience in the pharmaceutical and biopharma sectors. Their addition is aimed at strengthening Agilent's strategic direction during its three-year Ignite Transformation. The move follows the retirement of longtime board member Heidi Kunz, who served since the company's inception.
Read more →AAgilent Reports First-Quarter Fiscal Year 2025 Financial Results Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter
Agilent Technologies Inc. (NYSE A) reported first-quarter revenue of $1.68 billion for fiscal year 2025, reflecting a year-over-year growth of 1.4%. The company's non-GAAP earnings per share rose by 2% compared to the prior year, while GAAP net income decreased by 6%. Agilent has confirmed its full-year revenue outlook range between $6.68 billion and $6.76 billion, signaling continued expectations for growth. However, challenges remain, notably in the Applied Markets Group, which experienced a revenue decline of 4% year-over-year.
Read more →ADocument AGILENT TECHNOLOGIES, INC. LIFE SCIENCES AND DIAGNOSTICS MARKETS SEGMENT (Unaudited) (In millions, except margins data) FY24 Q1 Q2 Q3 Q4 Total Revenue $ 620 $ 604 $ 585 $ 657 $ 2,466 Gross margin % 54.9 % 55.1 %
Agilent Technologies, Inc. reported its financial results for the fiscal year 2024, revealing a total revenue of $2,466 million, down from $2,780 million in FY23. The company experienced a decline in gross margin from 56.7% to 54.5% over the year. Notably, income from operations reached $141 million in Q4 FY24, demonstrating an increase compared to previous quarters. The overall trends reflect a challenging year in terms of revenue and margins, despite some operational improvements.
Read more →AAgilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results Delivers solid results in Q4 initiates FY25 guidance Fourth-quarter fiscal year 2024 Revenue of $1.70 billion, up 0.8% reported and down 0.3% core (1) fro
Agilent Technologies Inc. reported its fourth-quarter fiscal year 2024 financial results, revealing a slight increase in revenue but a drop in GAAP net income compared to the previous year. The company is forecasting growth for fiscal year 2025, with expectations of revenue between $6.790 billion and $6.870 billion. Although non-GAAP earnings showed a year-over-year increase for the fourth quarter, challenges remain with overall revenue declining for the full fiscal year. Agilent plans to provide further details about its transformation strategy and market approach during an investor day in December 2024.
Read more →AAgilent Announces New Organizational Structure to Support its Market-Focused Strategy
Agilent Technologies has announced a new organizational structure focused on a market-centric strategy, effective immediately. This restructuring aims to enhance collaboration and support higher growth by organizing its businesses according to end markets and customer needs. The new leadership roles within the three business groups are designed to strengthen Agilent's market presence in Life Sciences, Applied Markets, and support services. The company plans to elaborate on this strategy further during its upcoming Analyst and Investor Day scheduled for December 17, 2024.
Read more →AAgilent Reports Third-Quarter Fiscal Year 2024 Financial Results Delivers better-than-expected performance raises mid-point of guidance Highlights Revenue of $1.58 billion, down 5.6% reported and 4.4% core (1) from the t
Agilent Technologies Inc. reported its third-quarter fiscal year 2024 financial results, revealing a revenue of $1.58 billion, down 5.6% from the previous year. Despite the decline in revenue, GAAP net income rose 155%, indicating strong operational performance that surpassed management's guidance. The company adjusted its full-year revenue outlook to between $6.450 billion and $6.500 billion, while also revising non-GAAP earnings guidance upward. However, several segments experienced revenue dips, pointing to challenges within specific areas of the business.
Read more →AAgilent Reports Second-Quarter Fiscal Year 2024 Financial Results Full-year outlook revised to reflect slower market recovery Announces plan to repurchase $0.75 billion of its common stock by end of fiscal year Board of
Agilent Technologies Inc. reported its second-quarter financial results for fiscal year 2024, showing an overall revenue decline of 8.4% year-over-year, amounting to $1.57 billion. Despite the decrease, GAAP net income increased to $308 million with an EPS of $1.05, reflecting a 3% growth from the prior year. Agilent has revised its full-year revenue outlook downward and announced a $0.75 billion stock repurchase plan, alongside a newly authorized $2.0 billion buyback program. The management remains optimistic about future market opportunities, although the market recovery is anticipated to be slower than expected.
Read more →AAgilent Announces Hans E. Bishop Has Stepped Down from Board of Directors
Agilent Technologies Inc. has announced that Hans E. Bishop, a board member since 2017, has stepped down from his position. Despite his departure, Bishop will continue to provide informal advisory support to Agilent and its CEO, Padraig McDonnell. The chairman expressed gratitude for Bishop's contributions, highlighting his importance to the board. Bishop expressed confidence in Agilent's future and acknowledged the company's crucial role in the evolving pharmaceutical landscape.
Read more →APadraig McDonnell Assumes Agilent CEO Role
Agilent Technologies has announced Padraig McDonnell as the new CEO, effective immediately. McDonnell, previously president of Agilent's CrossLab Group, brings over 26 years of experience in the analytical and scientific instrument industry. His appointment is part of a planned CEO transition and follows the tenure of Mike McMullen, who will remain as an adviser until October 31. McDonnell aims to advance Agilent's mission and enhance partnerships with customers.
Read more →AAgilent Reports First-Quarter Fiscal Year 2024 Financial Results Revenue and earnings exceed Q1 guidance Full-year outlook maintained Highlights Revenue of $1.66 billion, down 5.6% reported and 6.4% core (1) from the fir
Agilent Technologies Inc. reported its financial results for the first quarter of fiscal year 2024, revealing a revenue of $1.66 billion which is down 5.6% from the prior year. Although the company's earnings surpassed guidance, key segments such as Life Sciences experienced notable declines in revenue. Maintaining its full-year revenue outlook, Agilent remains cautiously optimistic about future growth potential amid current market challenges. The non-GAAP earnings guidance for the fiscal year also remained unchanged.
Read more →ACEO, he led Agilent's transformation into a market leading life-sciences and diagnostics company after the spin-off of the company's electronic measurement business, now Keysight Technologies. Agilent's market capitaliza
Agilent Technologies announced the retirement of CEO Mike McMullen and the appointment of Padraig McDonnell as CEO-elect and COO. McDonnell, who has worked with Agilent for 26 years and has held various leadership positions, will officially take over on May 1. McMullen's leadership saw the company's market capitalization nearly triple, and both he and the Board express confidence in McDonnell's ability to continue this growth trajectory. Agilent’s focus on innovation and customer satisfaction is expected to persist under McDonnell's leadership.
Read more →ADocument AGILENT TECHNOLOGIES, INC. LIFE SCIENCES AND APPLIED MARKETS SEGMENT (Unaudited) All periods below were recast to reflect the movement of the Cell Analysis division to our Diagnostics and Genomics business segme
Agilent Technologies has restructured its business segments by relocating the Cell Analysis division to the Diagnostics and Genomics segment. In FY23, the Life Sciences and Applied Markets segment generated a total revenue of $3,510 million, with a steady gross margin. However, the Diagnostics and Genomics segment saw a slight decrease in revenue compared to the previous year. Overall, while some segments demonstrated stability, there are challenges with profitability and revenue growth in others, influenced by rising R&D costs.
Read more →AAgilent Makes Strategic Updates to Organizational Structure
Agilent Technologies Inc. has announced the transfer of its Cell Analysis Division into the Diagnostics and Genomics Group to enhance growth opportunities. This strategic move is designed to integrate cell and molecular-based solutions and better serve customers in genomics and diagnostics. The restructuring aims to expand workflow coverage and accelerate growth for both organizations, beginning with the fiscal 2024 results. Agilent has previously enhanced its cell analysis capabilities through significant acquisitions in recent years.
Read more →AAgilent Reports Fourth-Quarter Fiscal Year 2023 Financial Results Revenue at the high end of guidance and EPS exceeds guidance Fourth-quarter fiscal year 2023 Revenue of $1.69 billion, down 8.7% reported and 9.7% core (1
Agilent Technologies Inc. announced its financial results for the fourth quarter of fiscal year 2023, reporting a revenue of $1.69 billion, which marks an 8.7% decrease from the previous year. Despite the revenue decline, the company achieved a GAAP net income of $475 million, or $1.62 per share, reflecting a 32% increase year-over-year. Looking ahead, Agilent projects a revenue range of $6.71 billion to $6.81 billion for fiscal year 2024, indicating a potential decline. The company remains optimistic about its strategic growth initiatives and market positioning.
Read more →AAgilent Names Philip Binns to Lead Life Sciences and Applied Markets Group
Agilent Technologies has appointed Philip Binns as the new president of its Life Sciences and Applied Markets Group, succeeding Jacob Thaysen. Binns, who has been with Agilent since 2010 and has extensive experience in the industry, previously served as the vice president and general manager for the Spectroscopy and Vacuum Solutions division. CEO Mike McMullen expressed confidence in Binns' ability to lead the group toward ongoing success, while acknowledging Thaysen's contributions during his tenure.
Read more →AAgilent Reports Third-Quarter Fiscal Year 2023 Financial Results Delivers on Q3 adjusts full-year outlook to reflect softer market conditions Highlights Reported revenue of $1.67 billion declined 2.7% year-over-year, and
Agilent Technologies Inc. reported its third-quarter fiscal year 2023 financial results, demonstrating mixed outcomes amidst challenging market conditions. The reported revenue for the quarter was $1.67 billion, reflecting a 2.7% decline year-over-year, while GAAP net income sharply fell by 65%. In contrast, non-GAAP net income showed a 7% increase, indicating some resilience in earnings. The company adjusted its full-year revenue outlook due to softer macroeconomic conditions, now expecting revenue between $6.80 billion and $6.85 billion.
Read more →AAgilent Reports Second-Quarter Fiscal Year 2023 Financial Results Delivers solid results adjusts full-year guidance in an increasingly challenging market Highlights Revenue of $1.72 billion represents 6.8% reported growt
Agilent Technologies Inc. reported its second-quarter fiscal year 2023 results, achieving a revenue of $1.72 billion, which represents a 6.8% year-over-year growth. The company adjusted its full-year revenue guidance to a range of $6.93 billion to $7.03 billion, reflecting cautious optimism amid a challenging market. GAAP net income was recorded at $302 million, and EPS increased by 12% compared to the previous year. Despite strong results, Agilent acknowledged that market uncertainties could impact future performance.
Read more →AAgilent Reports First-Quarter Fiscal Year 2023 Financial Results Delivers excellent start to the year raises full-year guidance Highlights Revenue of $1.76 billion represents 5% reported growth year-over-year and up 10%
Agilent Technologies Inc. reported a robust financial performance for the first quarter of fiscal year 2023, generating $1.76 billion in revenue, a 5% increase from the previous year. The company's GAAP net income was $352 million, showing a 28% year-over-year growth. Alongside these results, Agilent has raised its full-year revenue guidance to between $7.03 billion and $7.10 billion, reflecting a strong market position. The outlook for the second quarter also appears promising, with projected revenues of $1.655 billion to $1.680 billion.
Read more →AAgilent Authorizes $2 Billion Share Repurchase Program
Agilent Technologies Inc. has announced a new share repurchase program worth $2 billion, approved by its board of directors. Set to begin on March 1, 2023, this program aims to enhance shareholder returns and underscores the company's commitment to balanced capital deployment. It replaces the existing repurchase program and will be executed based on stock price fluctuations and market conditions. The company's CFO emphasized this move as a strategic element to drive growth and value for shareholders.
Read more →AAgilent Reports Fourth-Quarter and Fiscal Year 2022 Financial Results Outstanding fourth quarter caps off another strong year of performance in 2022 Fourth-quarter fiscal year 2022 Revenue of $1.85 billion represents 11%
Agilent Reports Fourth-Quarter and Fiscal Year 2022 Financial Results Outstanding fourth quarter caps off another strong year of performance in 2022 Fourth-quarter fiscal year 2022 Revenue of $1.85 billion represents 11% reported growth year-over-year and up 17% on a core(1) b
Read more →AAgilent Reports Third-Quarter Fiscal Year 2022 Financial Results Delivers excellent results again raises full-year guidance Highlights Revenue of $1.72 billion represents 8% reported growth year-over-year and up 13% on a
Agilent Reports Third-Quarter Fiscal Year 2022 Financial Results Delivers excellent results again raises full-year guidance Revenue of $1.72 billion represents 8% reported growth year-over-year and up 13% on a core(1) basis. GAAP net income of $329 million with earnings per sh
Read more →AAgilent Reports Second-Quarter Fiscal Year 2022 Financial Results Delivers solid results increases full-year core growth and EPS forecast Highlights Revenue of $1.61 billion represents 5% reported growth and up 7% on a c
Agilent Reports Second-Quarter Fiscal Year 2022 Financial Results Delivers solid results increases full-year core growth and EPS forecast Revenue of $1.61 billion represents 5% reported growth and up 7% on a core(1) basis. GAAP net income of $274 million with earnings per shar
Read more →AAgilent Reports First-Quarter Fiscal Year 2022 Financial Results Strong Start to 2022 Raising Full-Year Guidance Highlights Revenue of $1.67 billion represents 8% reported growth and up 9% on a core (1) basis. GAAP net i
Agilent Reports First-Quarter Fiscal Year 2022 Financial Results Strong Start to 2022 Raising Full-Year Guidance Revenue of $1.67 billion represents 8% reported growth and up 9% on a core(1) basis. GAAP net income of $283 million with earnings per share (EPS) of $0.93, flat fr
Read more →ADocument AGILENT TECHNOLOGIES, INC. LIFE SCIENCES AND APPLIED MARKETS SEGMENT (Unaudited) All periods below were revised to reflect the movement of the chemistries and supplies business and remarketed instruments busines
AGILENT TECHNOLOGIES, INC. LIFE SCIENCES AND APPLIED MARKETS SEGMENT (Unaudited) All periods below were revised to reflect the movement of the chemistries and supplies business and remarketed instruments business from our Agilent CrossLab business segment to our Life Sciences and
Read more →AAgilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results Fourth Quarter Caps Off Record-Setting Performance in 2021 Highlights Fourth-quarter fiscal year 2021 Revenue of $1.66 billion represents 12% reported
Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results Fourth Quarter Caps Off Record-Setting Performance in 2021 Fourth-quarter fiscal year 2021 Revenue of $1.66 billion represents 12% reported growth and up 11% on a core(1) basis. GAAP net income of $442 mill
Read more →ADr. Otis Brawley Named to Agilent Board of Directors Leading authority on cancer research joins Agilent board
Dr. Otis Brawley Named to Agilent Board of Directors Leading authority on cancer research joins Agilent board SANTA CLARA, Calif., Nov. 18, 2021 - Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Otis W. Brawley, a Bloomberg Distinguished Professor with the Departm
Read more →ADr. Mikael Dolsten Named to Agilent Board of Directors Pfizer executive brings strong scientific and medical expertise to Agilent board
Dr. Mikael Dolsten Named to Agilent Board of Directors Pfizer executive brings strong scientific and medical expertise to Agilent board SANTA CLARA, Calif., Sept. 23, 2021 - Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Mikael Dolsten, chief scientific officer a
Read more →AAgilent Reports Third-Quarter Fiscal Year 2021 Financial Results Delivers Very Strong Results, Raising Full-Year Guidance Highlights Revenue of $1.59 billion represents an increase of 26% reported growth year-over-year,
Agilent Reports Third-Quarter Fiscal Year 2021 Financial Results Delivers Very Strong Results, Raising Full-Year Guidance Revenue of $1.59 billion represents an increase of 26% reported growth year-over-year, up 21% on a core(1) basis. GAAP diluted earnings per share (EPS) of
Read more →AAgilent Reports Second-Quarter Fiscal Year 2021 Financial Results Delivers Strong, Broad-Based Growth Raising Full-Year Outlook on Continued Company Momentum Highlights Revenue of $1.525 billion represents an increase of
Agilent Reports Second-Quarter Fiscal Year 2021 Financial Results Delivers Strong, Broad-Based Growth Raising Full-Year Outlook on Continued Company Momentum Revenue of $1.525 billion represents an increase of 23% reported growth year-over-year, up 19% on a core(1) basis. GAA
Read more →AAgilent Technologies Announces Pricing of $850 Million of Senior Notes
Agilent Technologies Announces Pricing of $850 Million of Senior Notes SANTA CLARA, Calif., March 3, 2021 Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal am
Read more →AAgilent Reports First-Quarter Fiscal Year 2021 Financial Results Strong start to 2021, raising full-year guidance Highlights Revenue of $1.55 billion represents an increase of 14% reported growth year over year, up 11% o
Agilent Reports First-Quarter Fiscal Year 2021 Financial Results Strong start to 2021, raising full-year guidance Revenue of $1.55 billion represents an increase of 14% reported growth year over year, up 11% on a core(1) basis. GAAP net income of $288 million, or 93 cents per
Read more →AAgilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results Initiates Fiscal 2021 Guidance Highlights Fourth-quarter fiscal year 2020 Revenue of $1.48 billion represents 8% reported growth and up 6% on a core (
Agilent Reports Fourth-Quarter and Fiscal Year 2020 Financial Results Initiates Fiscal 2021 Guidance Fourth-quarter fiscal year 2020 Revenue of $1.48 billion represents 8% reported growth and up 6% on a core(1) basis with strong growth across all regions and all three business
Read more →AAgilent Reports Third-Quarter Fiscal Year 2020 Financial Results Highlights : Revenue of $1.26 billion represents decline of 1% reported growth year-over-year, down 3.1% on a core (1) basis GAAP net income of $199 millio
Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results SANTA CLARA, California, Aug. 18, 2020 - Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019
Read more →AAgilent Technologies Announces Pricing of $500 Million of Senior Notes
Agilent Technologies Announces Pricing of $500 Million of Senior Notes SANTA CLARA, Calif., June 1, 2020 Agilent Technologies, Inc. (NYSE: A) today announced the pricing of an underwritten, registered public offering of a series of its senior notes in an aggregate principal amo
Read more →AAgilent Reports Second-Quarter Fiscal Year 2020 Financial Results Highlights : Revenue of $1.24 billion represents flat reported growth, down 1.7% on a core (1) basis GAAP net income of $101 million, or 32 cents per shar
Agilent Reports Second-Quarter Fiscal Year 2020 Financial Results SANTA CLARA, Calif., May 21, 2020 - Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.24 billion for the second quarter ended April 30, 2020, equal to revenue reported for the second quarter of 2019
Read more →AAgilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21
Agilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21 SANTA CLARA, California, April 14, 2020 -- Agilent Technologies, Inc. (NYSE: A) today announced that due to the expanded and evolving nature of the COVID-19 pandemic and result
Read more →AAgilent Technologies to Adjourn Annual Meeting Until
Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020 SANTA CLARA, California, Mar. 17, 2020 - Agilent Technologies, Inc. (NYSE: A) today announced plans to adjourn its annual meeting of stockholders, originally scheduled to be held March 18, 2020, due to public he
Read more →AAgilent Technologies Reports First Quarter Fiscal Year 2020 Financial Results Highlights : Revenue of $1.36 billion represents 5.7% reported growth, up 2.4% on a core (1) basis GAAP net income of $197 million or 63 cents
Agilent Technologies Reports First Quarter Fiscal Year 2020 Financial Results SANTA CLARA, Calif., Feb. 18, 2020 - Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.36 billion for the first quarter ended Jan. 31, 2020, up 5.7% year over year (and up 2.4% on a core
Read more →AAgilent Announces CrossLab Group Leadership Transition Mark Doak to Retire May 1, Padraig McDonnell to lead Agilent CrossLab Group
Agilent Announces CrossLab Group Leadership Transition Mark Doak to Retire May 1, Padraig McDonnell to lead Agilent CrossLab Group SANTA CLARA, California, Jan. 23, 2020 -- Agilent Technologies Inc. (NYSE: A) today announced that Mark Doak, Agilent senior vice president and pre
Read more →AAgilent Technologies Reports Fourth-Quarter and Fiscal Year 2019 Financial Results Highlights : Fourth-quarter fiscal year 2019 Revenue of $1.37 billion represents 6% reported growth; and up 4% on a core (1) basis led by
Agilent Technologies Reports Fourth-Quarter and Fiscal Year 2019 Financial Results Fourth-quarter fiscal year 2019 SANTA CLARA, California, Nov. 25, 2019 - Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.37 billion for the fourth quarter ended Oct. 31, 2019, u
Read more →AAgilent Technologies Reports Third Quarter Fiscal Year 2019 Financial Results Highlights : Revenue of $1.27 billion represents 6 percent reported growth; and up 6 percent (1) on a core basis driven by strength in the pha
Agilent Technologies Reports Third Quarter Fiscal Year 2019 Financial Results SANTA CLARA, Calif., Aug. 14, 2019 - Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.27 billion for the third quarter ended July 31, 2019, up 6 percent year-over-year (and up 6 percen
Read more →AAgilent Technologies Reports Second Quarter Fiscal Year 2019 Financial Results Highlights : Revenue of $1.24 billion represents 3 percent reported growth and 4 percent core revenue (1) growth GAAP net income of $182 mill
Agilent Technologies Reports Second Quarter Fiscal Year 2019 Financial Results SANTA CLARA, Calif., May 14, 2019 - Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.24 billion for the second quarter ended April 30, 2019, up 3 percent year-over-year (up 4 percent
Read more →AAgilent Technologies Reports First-Quarter Fiscal Year 2019 Financial Results Strong Start to Year as First-Quarter Revenue and EPS Exceed Guidance; Raising Full Year Guidance Highlights: Revenue of $1.28 billion, repres
Agilent Technologies Reports First-Quarter Fiscal Year 2019 Financial Results Strong Start to Year as First-Quarter Revenue and EPS Exceed Guidance; Raising Full Year Guidance SANTA CLARA, Calif., February 20, 2019 Agilent Technologies, Inc. (NYSE: A) today reported revenue o
Read more →ACONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
AGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) Three Months Ended January 31, 2018 As Previously Reported Pension Adjustment As Adjusted Net revenue $ 1,211 $ 1,211 Costs and expenses:
Read more →AMala Anand to Join Agilent's Board of Directors SAP SE executive brings deep knowledge of software and analytics space
Mala Anand to Join Agilent's Board of Directors SAP SE executive brings deep knowledge of software and analytics space SANTA CLARA, Calif., Jan. 16, 2019 - Agilent Technologies, Inc. (NYSE: A) today announced that Mala Anand, president, Intelligent Enterprise Solutions and Indu
Read more →AAgilent Technologies Reports Fourth-Quarter Fiscal Year 2018 Financial Results Agilent delivers outstanding quarter wrapping up an excellent 2018 Highlights: Fourth Quarter Q4 revenue of $1.29 billion, representing growt
Agilent Technologies Reports Fourth-Quarter Fiscal Year 2018 Financial Results Agilent delivers outstanding quarter wrapping up an excellent 2018 SANTA CLARA, Calif., November 19, 2018 Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.29 billion for the fourth-
Read more →AAgilent Technologies Reports Third-Quarter Fiscal Year 2018 Financial Results Company Tops Third Quarter Revenue and EPS Guidance Raising Full-Year Guidance Highlights: Revenue of $1.20 billion, representing growth of 8
Agilent Technologies Reports Third-Quarter Fiscal Year 2018 Financial Results Company Tops Third Quarter Revenue and EPS Guidance Raising Full-Year Guidance SANTA CLARA, Calif., August 14, 2018 Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.20 billion for t
Read more →AAgilent Announces CFO Transition Didier Hirsch to Retire Oct. 31 Robert W. McMahon to Become Chief Financial Officer
Agilent Announces CFO Transition Didier Hirsch to Retire Oct. 31 Robert W. McMahon to Become Chief Financial Officer SANTA CLARA, Calif., July 31, 2018 Agilent Technologies Inc. (NYSE: A) today announced that Didier Hirsch, senior vice president and chief financial officer, h
Read more →AAGILENT TECHNOLOGIES, INC. LIFE SCIENCES AND APPLIED MARKETS GROUP (Unaudited) (In millions, except margins data) 2018 Q1 Q2 Q3 Q4 Total Net revenue $ 596 $ 537 Gross margin % 62.1 % 59.7 % Income from operations $ 156 $
AGILENT TECHNOLOGIES, INC. LIFE SCIENCES AND APPLIED MARKETS GROUP (Unaudited) (In millions, except margins data) 2018 Q1 Q2 Q3 Q4 Total Net revenue $ 596 $ 537 Gross margin % 62.1 % 59.7 % Income from operations $ 156 $ 113 Operating margi
Read more →AAgilent Technologies Reports Second-Quarter Fiscal Year 2018 Financial Results Strong Quarter, Reaffirming Full Year Guidance Highlights: Revenue of $1.21 billion, representing growth of 9 percent (core revenue growth of
Agilent Technologies Reports Second-Quarter Fiscal Year 2018 Financial Results Strong Quarter, Reaffirming Full Year Guidance SANTA CLARA, Calif., May 14, 2018 Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.21 billion for the second quarter ended April 30, 2
Read more →AAgilent Announces Departure of Patrick Kaltenbach
Agilent Announces Departure of Patrick Kaltenbach SANTA CLARA, Calif., April 16, 2018 Agilent Technologies Inc. (NYSE: A) today announced that Patrick Kaltenbach, senior vice president, Agilent and president, Life Sciences and Analytical Group (LSAG), will leave the company on
Read more →AAgilent Technologies Reports First-Quarter Fiscal Year 2018 Financial Results Excellent Start to 2018; Raising Full Year Guidance Highlights: Revenue of $1.21 billion, representing growth of 14 percent (core revenue grow
Agilent Technologies Reports First-Quarter Fiscal Year 2018 Financial Results Excellent Start to 2018; Raising Full Year Guidance SANTA CLARA, Calif., February 14, 2018 Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.21 billion for the first-quarter ended Jan
Read more →ADow R. Wilson to Join Agilent's Board of Directors CEO of Varian Medical Systems brings deep knowledge of the healthcare industry
Dow R. Wilson to Join Agilent's Board of Directors CEO of Varian Medical Systems brings deep knowledge of the healthcare industry SANTA CLARA, Calif., Jan 18, 2018 - Agilent Technologies, Inc. (NYSE: A) today announced that Dow R. Wilson, CEO of Varian Medical Systems, Inc., ha
Read more →AAgilent Technologies Reports Fourth-Quarter Fiscal Year 2017 Financial Results Agilent Caps Stellar Year with Strong Q4 Results Highlights: GAAP net income of $177 million, or $0.54 per share Non-GAAP net income of $218
Agilent Technologies Reports Fourth-Quarter Fiscal Year 2017 Financial Results Agilent Caps Stellar Year with Strong Q4 Results SANTA CLARA, Calif., November 20, 2017 Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.19 billion for the fourth-quarter ended Octo
Read more →AINVESTOR CONTACT: Alicia Rodriguez +1 408 345 8948 alicia_rodriguez@agilent.com EDITORIAL CONTACT: Stefanie Notaney +1 408 345 8955 stefanie.notaney@agilent.com Agilent Technologies Reports Third-Quarter Fiscal Year 2017
alicia_rodriguez@agilent.com stefanie.notaney@agilent.com Agilent Technologies Reports Third-Quarter Fiscal Year 2017 Financial Results Strong Third Quarter, Raising Full Year Guidance SANTA CLARA, Calif., August 15, 2017 -- Agilent Technologies, Inc. (NYSE: A) today reporte
Read more →AHans E. Bishop to Join Agilent's Board of Directors CEO of Juno Therapeutics brings deep knowledge of the biopharma industry
Hans E. Bishop to Join Agilent's Board of Directors CEO of Juno Therapeutics brings deep knowledge of the biopharma industry SANTA CLARA, Calif., July 18, 2017 - Agilent Technologies, Inc. (NYSE: A) today announced that Hans E. Bishop, CEO of Juno Therapeutics, has been elected
Read more →AINVESTOR CONTACT: Alicia Rodriguez +1 408 345 8948 alicia_rodriguez@agilent.com EDITORIAL CONTACT: Stefanie Notaney +1 408 345 8955 stefanie.notaney@agilent.com Agilent Technologies Reports Second-Quarter Fiscal Year 201
alicia_rodriguez@agilent.com stefanie.notaney@agilent.com Agilent Technologies Reports Second-Quarter Fiscal Year 2017 Financial Results Strong Second Quarter, Raises Full-Year Guidance SANTA CLARA, Calif., May 22, 2017 -- Agilent Technologies Inc. (NYSE: A) today reported r
Read more →AAgilent Technologies Reports First-Quarter 2017 Results Strong Start to 2017, Increasing Core Revenue Growth Guidance Highlights: GAAP net income of $168 million, or $0.52 per share Non-GAAP net income of $172 million, o
Agilent Technologies Reports First-Quarter 2017 Results Strong Start to 2017, Increasing Core Revenue Growth Guidance SANTA CLARA, Calif., Feb. 14, 2017 Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.07 billion, up 3.8 percent year over year (up 4.8 percent
Read more →Competitive Position
How A ranks across every disease it competes inCompetitive Position is a premium feature
See how A ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial